Multiple randomized controlled trials including the SUSTAIN series demonstrate that GLP-1 therapy improves HOMA-IR (a measure of insulin resistance) and fasting insulin levels independent of weight loss alone
IGF-1 LR3 (1 mg) is a synthetic recombinant analog of insulin-like growth factor-1 (IGF-1), categorized under growth factor and muscle biology research peptides, and supplied exclusively for laboratory research use
It not only successfully regulates blood sugar levels [1] but also reduces the appetite and, thereby, the weight of patients [2], especially in individuals with obesity and type 2 diabetes mellitus (T2DM)
Authors note: Why not regenerate the tissue and provide a new barrier
The exact schedule depends on your starting health, your other medications, and how you tolerate the drug
While these numbers show effectiveness, they also suggest that expectations should be managed, especially given the significant financial investment